Abivax (ABVX) Current Deferred Revenue (2023)

Abivax's (ABVX) quarterly Current Deferred Revenue came in at $55948.9 in Q4 2023.

Abivax (ABVX) Current Deferred Revenue (2023) Analysis & Trends

Abivax's Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $55948.9 for Q4 2023.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $55948.9 in Q4 2023; TTM through Dec 2023 was $55948.9, a N/A change from a year earlier, with the FY2023 full-year figure at $55948.9, changed N/A from the prior year.
Current Deferred Revenue steadied at $55948.9 in Q4 2023 per ABVX's latest filing.
Across five years, Current Deferred Revenue topped out at $55948.9 in Q4 2023 and bottomed at $55948.9 in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Abivax	10.36 Bn	10.36 Bn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	55,948.88